Predictive Oncology (POAI) - 2024 Q4 - Annual Results

Financial Performance - For the year ended December 31, 2024, Predictive Oncology reported a loss from continuing operations of approximately $10.8 million on total revenue of$1.6 million[1] - The company recorded revenue of $1,623,817 in 2024, a slight decrease from$1,627,697 in 2023, primarily derived from its Eagan operating segment[9] - Basic and diluted net loss per common share from continuing operations decreased approximately 33% to $1.99 in 2024, compared to$2.99 in 2023[9] - Cash and cash equivalents decreased to $734,673 as of December 31, 2024, down from$8.7 million as of December 31, 2023[9] - General and administrative expenses decreased by $961,025 to$7,419,892 in 2024 from $8,380,917 in 2023, primarily due to lower employee-related expenses[9] Strategic Initiatives - The company announced an agreement to merge with Renovaro, which is expected to enhance its AI/ML drug discovery capabilities[2] - Predictive Oncology plans to launch its ChemoFx drug response assay in Europe, initially focusing on ovarian and other gynecological cancers[5] Revenue Growth - The Eagan operating segment contributed$1,539,005 in revenue for 2024, compared to $1,135,101 in 2023, indicating growth in this segment[9] Financing Activities - Predictive Oncology received more than$3.0 million in combined gross proceeds during the first three months of 2025 from various financing activities[5] Asset Management - The company completed the sale of assets related to its subsidiary, Skyline Medical Inc., to DeRoyal Industries, which is expected to reduce ongoing expenses significantly[5]